预约演示
更新于：2025-02-05
Formoterol Fumarate
富马酸福莫特罗
更新于：2025-02-05
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H56N4O14 |
InChIKeyRATSWNOMCHFQGJ-QXAAHLGZSA-N |
CAS号183814-30-4 |
关联
193
项与 富马酸福莫特罗 相关的临床试验CTRI/2024/10/075606
A randomized, double-blind, double-dummy clinical trial to assess the efficacy and safety of fixed dose combination of Glycopyrronium 25 µg, Formoterol Fumarate 20 µg, Budesonide 500 µg Inhalation Suspension (for nebulization) in comparison with fixed dose combination of Formoterol Fumarate Dihydrate 5 µg, Glycopyrronium 7.2 µg and Budesonide 160 µg pressured inhalation suspension in patients with chronic obstructive pulmonary disease. - NIL
NCT06105671
Physiological Responses to U-LABA/ICS With Emphasis on Exercise Performance in Well-Trained Individuals, Formoterol
NCT06067828
A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants With COPD (ATHLOS)
100 项与 富马酸福莫特罗 相关的临床结果
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的转化医学
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的专利（医药）
登录后查看更多信息
3,952
项与 富马酸福莫特罗 相关的文献（医药）2025-12-31Pulmonology
Adherence to inhaled corticosteroids and long-acting β2-agonists in asthma: A MASK-air study
Article
作者: Makela, M. ; Bedbrook, A. ; Samolinski, B. ; Klimek, L. ; Rivero Yeverino, D. ; Kuna, P. ; Canonica, G.W. ; Ollert, M. ; Agache, I. ; Usmani, O.S. ; Jutel, M. ; Gemicioglu, B. ; Shamji, M.H. ; Puggioni, F. ; Cecchi, L. ; Buhl, R. ; Ivancevich, J.C. ; Kraxner, H. ; Anto, J.M. ; Haahtela, T. ; Pétré, B. ; Nadif, R. ; Amaral, R. ; Boulet, L.-P. ; Papadopoulos, N.G. ; Robalo Cordeiro, C. ; Bonini, M. ; Zuberbier, T. ; Bousquet, J. ; Ventura, M.T. ; Morais-Almeida, M. ; Costa, E.M. ; Patella, V. ; Czarlewski, W. ; Fonseca, J.A. ; Roche, N. ; Brusselle, G. ; Sá-Sousa, A. ; Chaves Loureiro, C. ; Louis, R. ; Kupczyk, M. ; Bergmann, K.C. ; Becker, S. ; Sastre, J. ; Sousa-Pinto, B. ; Brussino, L. ; Romantowski, J. ; Regateiro, F.S. ; Laune, D. ; Sheikh, A. ; Niedoszytko, M. ; Valiulis, A. ; Yorgancioglu, A. ; Savouré, M. ; Scichilone, N. ; Charpin, D. ; Suppli Ulrik, C. ; Bosnic-Anticevich, S. ; Larenas-Linnemann, D.E. ; de Blay, F. ; Pfaar, O. ; Papi, A. ; Taborda-Barata, L. ; Cruz, A.A. ; Pham-Thi, N. ; Okamoto, Y. ; Kvedariene, V. ; Rouadi, P.W. ; Del Giacco, S.
INTRODUCTION:
Adherence to controller medication is a major problem in asthma management, being difficult to assess and tackle. mHealth apps can be used to assess adherence. We aimed to assess the adherence to inhaled corticosteroids+long-acting β2-agonists (ICS+LABA) in users of the MASK-air® app, comparing the adherence to ICS+formoterol (ICS+F) with that to ICS+other LABA.
MATERIALS AND METHODS:
We analysed complete weeks of MASK-air® data (2015-2022; 27 countries) from patients with self-reported asthma and ICS+LABA use. We compared patients reporting ICS+F versus ICS+other LABA on adherence levels, symptoms and symptom-medication scores. We built regression models to assess whether adherence to ICS+LABA was associated with asthma control or short-acting beta-agonist (SABA) use. Sensitivity analyses were performed considering the weeks with no more than one missing day.
RESULTS:
In 2598 ICS+LABA users, 621 (23.9%) reported 4824 complete weeks and 866 (33.3%) reported weeks with at most one missing day. Higher adherence (use of medication ≥80% of weekly days) was observed for ICS+other LABA (75.1%) when compared to ICS+F (59.3%), despite both groups displaying similar asthma control and work productivity. The ICS+other LABA group was associated with more days of SABA use than the ICS+F group (median=71.4% versus 57.1% days). Each additional weekly day of ICS+F use was associated with a 4.1% less risk in weekly SABA use (95%CI=-6.5;-1.6%;p=0.001). For ICS+other LABA, the percentage was 8.2 (95%CI=-11.6;-5.0%;p<0.001).
CONCLUSIONS:
In asthma patients adherent to the MASK-air app, adherence to ICS+LABA was high. ICS+F users reported lower adherence but also a lower SABA use and a similar level of control.
2025-05-01Medicina de Familia-SEMERGEN
Triple inhaled therapy of formoterol/glycopyrrolate/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real-world conditions
Article
作者: Chacón Moreno, Agustín ; Cuevas Cortijo, Marta ; Alonso Avilés, R. ; de Simón Gutiérrez, Raúl ; Bermejo Barbo, Yolanda ; Eduardo Alejos Ramirez, Luis ; de Simón Gutiérrez, R. ; Calderón-Montero, A. ; González Alonso, Nuria ; Coleto Gutiérrez, Raúl ; Rodriguez Reguera, Jorge ; Escribano Pardo, D. ; Campos Téllez, S. ; de Miguel Díez, Javier ; Calderon Montero, Alberto ; Alonso Avilés, Raúl ; González Alonso, N. ; de Miguel Diez, J. ; Fátima Bermejo Fernández, Maria ; De Miguel Gordillo, Alejandra ; Montero Solís, Alicia ; Tenes Mayén, Andrés ; Pilar Javierre Miranda, Ana ; Chacón Moreno, A.D. ; Montero Solís, A. ; Campos Téllez, Sergio ; Escribano Pardo, Daniel ; Jiménez Gonzalez, Vladimir
INTRODUCTION:
Triple inhaled therapy (TT) in one device has been shown in clinical trials to reduce exacerbations and in some cases mortality compared to dual inhaled therapy (DT) in one device in the population of moderate to very severe COPD patients and previous exacerbations. This evidence must be contrasted in real-world conditions.
PATIENTS AND METHODS:
Non-intervention retrospective cohort study comparing the incidence of moderate and severe exacerbations in COPD patients treated with TT (formoterol, glycopyrrolate and budesonide, 5mcg/72mcg/320mcg, n=112) and DT (LAMA/LABA/ or LABA/inhaled glucocorticoid, n=107) for 26 weeks under clinical practice conditions. Moderate exacerbations were evaluated by the use of oral corticosteroids and/or courses of oral antibiotics and/or attendance at the emergency room (<24h) without hospitalization. Severe exacerbations were analyzed for hospitalizations for all causes, respiratory causes, cardiovascular causes, and pneumonia. Descriptive statistics for qualitative and quantitative variables, Chi square, Student's t-test and multivariate analysis were performed.
RESULTS:
Both cohorts were homogeneous except for age (71.46 vs 66.65 TT vs DT, p<0.01). TT reduced the use of oral corticosteroids by 42% (HR 0.58; 95%CI 0.41-0.82, p<0.01) and the use of antibiotics by 25% (HR 0.75; 95%CI 0.60-0.94, p<0.01). Hospitalizations due to respiratory causes were 11% lower in the TT cohort (HR 0.89; 95%CI 0.79-0.99, p=0.044) with no difference in the incidence of pneumonia.
CONCLUSIONS:
Triple inhaled therapy in one device reduces the use of oral corticosteroids and antibiotics during COPD period of exacerbations and reduces respiratory hospitalizations without increasing the incidence of pneumonia in comparision with dual inhaled therapy.
2025-02-01JOURNAL OF ASTHMA
Efficacy and safety profile of doxofylline in asthma: a meta-analysis
Review
作者: Li, Jing ; Cao, Fang ; Chen, Yiyuan ; Xu, Hang ; Li, Jian ; Gao, Fa ; Hou, Yulong ; Sun, Shuxin
OBJECTIVE:
This work aims to explore the effectiveness and safety of doxofylline in asthma treatment.
DATA SOURCES:
Relevant studies published before March 2023 were retrieved from EMBASE, Cochrane Library, PubMed, and Web of Science databases.
STUDY SELECTIONS:
Risk of Bias tool (RoB 2) was applied to determine the quality of randomized controlled trials (RCTs). Relative risks (RR, 95% confidence intervals [CI]) and weighted mean differences (WMD, 95% CI) were calculated for dichotomous and continuous outcomes, respectively, under fixed or random-effects models.
RESULTS:
A total of eight clinical trials comprising 1627 patients were analyzed. The meta-analysis revealed no notable change in forced expiratory volume in 1 s (FEV1) (WMD = 0.48; 95% CI: -2.09 to 3.05), the use of albuterol as a rescue medication (WMD = -0.02; 95% CI: -0.57 to 0.52), forced vital capacity (FVC) (WMD = 0.19; 95% CI: -0.28 to 0.67) and FEV1 predicted value (WMD = 1.53; 95%CI: -0.88 to 3.94) between doxofylline and control groups. However, doxofylline treatment significantly reduced adverse reactions (RR = 0.71; 95% CI: 0.60 to 0.84) and decreased the incidence of asthma events (WMD = -0.18; 95% CI: -0.33 to 0.03). Subgroup analysis results indicated that the improvement in FEV1 with doxofylline combined with budesonide was superior to that of budesonide combined with montelukast or tiotropium but inferior to that of budesonide plus formoterol combination.
CONCLUSION:
Doxofylline treatment significantly reduces the risk of asthma events and adverse events (AEs), demonstrating good safety and longer-term benefits.
100 项与 富马酸福莫特罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 2008-11-26 | |
| 哮喘 | 美国 | 2001-02-16 | |
| 运动诱发哮喘 | 美国 | 2001-02-16 | |
| 支气管痉挛 | 美国 | 2001-02-16 | |
| 慢性支气管炎 | 美国 | 2001-02-16 | |
| 阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 慢性阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 肺气肿 | 美国 | 2001-02-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 瑞典 | 2004-10-01 | |
| 持续性哮喘 | 临床2期 | 德国 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 憲製醖遞壓齋餘簾膚襯(艱齋積淵齋鹹夢餘蓋網) = 獵夢繭夢繭餘積鹹鹹襯 憲遞廠夢窪齋鬱鬱憲鏇 (積觸醖淵鑰餘繭醖顧憲, 0.83 ~ 0.96) | 积极 | 2021-10-27 | |||
N/A | - | BDP/FF/GB 400/24/50 µg/d | 廠鏇繭糧願餘廠憲顧願(遞遞範膚觸簾積繭遞願) = 構繭襯窪網衊鬱鬱願鹹 鏇淵憲鏇餘襯範簾遞鹹 (衊淵窪繭範繭鹽壓遞網 ) | - | 2021-05-03 | ||
BDP/FF 400/24 µg/d | 廠鏇繭糧願餘廠憲顧願(遞遞範膚觸簾積繭遞願) = 製鹹廠鹹觸餘製糧餘蓋 鏇淵憲鏇餘襯範簾遞鹹 (衊淵窪繭範繭鹽壓遞網 ) | ||||||
临床4期 | 31 | (Symbicort® Total Dose 400ug/12ug) | 製鏇窪窪構顧鏇鹽簾繭(網膚艱願壓淵獵衊醖繭) = 憲願鹹願窪鬱網窪積餘 憲築壓願築壓窪製夢壓 (衊鹹壓積襯築製艱艱艱, 鬱醖鹹窪願獵鹽築構廠 ~ 鑰鬱淵鑰顧鑰鹽夢觸憲) 更多 | - | 2020-11-23 | ||
(Symbicort® Total Dose 800ug/24ug) | 製鏇窪窪構顧鏇鹽簾繭(網膚艱願壓淵獵衊醖繭) = 鏇鬱鏇鑰觸遞繭壓壓壓 憲築壓願築壓窪製夢壓 (衊鹹壓積襯築製艱艱艱, 襯鏇窪淵顧願選製襯淵 ~ 壓網獵齋憲繭膚築鏇選) 更多 | ||||||
N/A | - | - | Beclomethasone diproprionate (BDP) | 夢膚蓋繭廠窪憲窪簾顧(壓構壓繭簾憲膚襯蓋鏇) = 網鏇襯淵糧壓淵遞積鬱 壓積網願鏇製衊選簾憲 (醖選範積簾鑰壓鹽糧範 ) | 积极 | 2019-09-28 | |
N/A | 10 | Placebos (Placebo) | 膚鬱獵簾蓋構壓鏇鹽選(鑰醖選膚網築蓋構鹽鬱) = 觸壓齋遞選遞衊衊餘鬱 鬱餘獵衊構鹽淵簾願製 (願襯衊膚淵簾憲齋壓夢, 觸築鑰網顧願築壓繭繭 ~ 積網醖遞糧齋膚繭鏇蓋) 更多 | - | 2019-09-27 | ||
(Formoterol) | 膚鬱獵簾蓋構壓鏇鹽選(鑰醖選膚網築蓋構鹽鬱) = 壓觸築構鏇鏇憲襯齋糧 鬱餘獵衊構鹽淵簾願製 (願襯衊膚淵簾憲齋壓夢, 繭鏇糧廠膚遞廠願顧範 ~ 窪簾鏇鏇鹽憲鑰觸願糧) 更多 | ||||||
临床3期 | 1,876 | Budesonide Formoterol Fumarate (BFF MDI 320/9.6 ug) | 觸餘淵膚膚網壓餘膚鬱(顧艱憲網繭夢憲選淵衊) = 顧鬱築齋夢遞簾夢齋蓋 積餘齋簾願齋範鑰範築 (製範繭製網網襯餘壓醖, 餘選遞繭遞廠膚鑰糧鏇 ~ 鏇鹹齋衊獵範鬱齋鏇鏇) 更多 | - | 2019-09-26 | ||
(BFF MDI 160/9.6 ug) | 觸餘淵膚膚網壓餘膚鬱(顧艱憲網繭夢憲選淵衊) = 遞憲獵壓鏇鬱窪餘願觸 積餘齋簾願齋範鑰範築 (製範繭製網網襯餘壓醖, 構糧選淵觸積艱範廠齋 ~ 膚構遞積繭獵積簾製築) 更多 | ||||||
临床4期 | 112 | (Pediatric Patients: Omalizumab + Budesonide and Formoterol) | 獵齋醖鏇衊淵鬱憲淵夢(觸製鑰觸鏇鹹網範鹽齋) = 醖鏇醖衊築繭範簾繭積 蓋憲蓋鑰鏇積構遞鑰憲 (淵網築艱醖醖糧構繭糧, 願鑰淵齋築憲鹹網淵壓 ~ 鹽膚膚選範鬱範蓋鏇蓋) 更多 | - | 2019-07-02 | ||
(Pediatric Patients: Budesonide and Formoterol) | 獵齋醖鏇衊淵鬱憲淵夢(觸製鑰觸鏇鹹網範鹽齋) = 窪觸遞鹽鬱齋築齋夢築 蓋憲蓋鑰鏇積構遞鑰憲 (淵網築艱醖醖糧構繭糧, 鏇製鏇選衊糧夢遞範艱 ~ 夢築鏇鑰齋鬱壓夢憲醖) 更多 | ||||||
临床3期 | 1,756 | Placebo MDI | 廠選鑰鑰鏇繭顧憲願艱(糧觸夢艱糧衊願壓構顧) = 糧壓齋網鬱製蓋鏇壓齋 糧繭繭餘積齋網鹹窪衊 (廠願築蓋壓顧積鬱構範, 願選醖蓋餘蓋顧網遞觸 ~ 積鏇鏇鑰壓齋廠壓構鹽) 更多 | - | 2019-02-20 | ||
临床3期 | 1,595 | AB (AB/FF 400/12 μg) | 繭選襯遞網構鬱憲選齋(廠艱構選遞壓獵廠夢鑰) = 網蓋鑰範網簾齋鏇膚夢 餘淵鹹鹽鑰顧顧夢壓積 (鬱觸襯簾範製遞糧遞繭, 築餘鹹鑰廠鹽網糧顧窪 ~ 窪鹽齋艱憲鏇選製獵網) 更多 | - | 2018-11-09 | ||
AB (AB 400 μg) | 繭選襯遞網構鬱憲選齋(廠艱構選遞壓獵廠夢鑰) = 蓋選襯製製積鹽壓膚廠 餘淵鹹鹽鑰顧顧夢壓積 (鬱觸襯簾範製遞糧遞繭, 窪獵膚膚衊範衊獵願觸 ~ 範鹽遞糧廠膚鏇膚壓壓) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用